H.R. 1518

119th Congress

In Committee

New Era of Preventing End-Stage Kidney Disease Act

Sponsored byRepublican:Rep. Bilirakis, Gus M. [R-FL-12]FL· Introduced 24 February 2025

56

Cosponsors

4

Actions

0

Amendments

2

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

24 February 2025·1 year ago

Summary

Introduced in House · Updated 13 August 2025

New Era of Preventing End-Stage Kidney Disease Act

This bill establishes regional centers of excellence, postgraduate fellowships, and training for health professionals relating to the diagnosis and treatment of rare kidney disease. It also requires the Department of Health and Human Services (HHS) to conduct various studies on rare kidney disease.

Specifically, it authorizes the National Institute of Diabetes and Digestive and Kidney Diseases to award funding to public and private nonprofit entities for establishing regional centers of excellence that will increase public awareness, conduct research, and develop resources for diagnosing and treating rare kidney diseases. A center may receive such funding for up to five years, unless extended by the institute. 

The bill also requires health professions schools receiving a grant from the Health Resources and Services Administration (HRSA) Centers of Excellence program to award fellowships for training on preventing, diagnosing, and treating rare kidney disease in disproportionately impacted populations.

Also, the bill expands the priorities of HRSA’s Primary Care Training and Enhancement program to include training for health care workers to care for individuals with kidney disease.

Additionally, HHS must conduct several studies and report to Congress on topics such as treating rare kidney disease in disproportionately affected populations, eliminating the need for dialysis or kidney transplants, and increasing public awareness of rare kidney disease.

Timeline

4 actions

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    24 February 2025 · IntroReferral

  2. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    24 February 2025 · IntroReferral

  3. Introduced in House

    24 February 2025 · IntroReferral

  4. Introduced in House

    24 February 2025 · IntroReferral

Sponsorship

56 cosponsors

Cosponsors

  • Democrat3876%
  • Republican1224%

Classification

Policy area

Health

Legislative subjects

Congressional oversightDigestive and metabolic diseasesGeneticsGovernment studies and investigationsHealth care coverage and accessHealth programs administration and fundingHealth promotion and preventive careMedical educationMedical researchMedical tests and diagnostic methodsResearch administration and funding

Committees

2

  • Energy and Commerce Committee

    House · Standing

    • Referred To24 Feb 2025
  • Ways and Means Committee

    House · Standing

    • Referred To24 Feb 2025
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.